[Refractory Dyspnea in Advanced COPD: Palliative Treatment with Opioids]

Area of Science:

• Pulmonary Medicine
• Palliative Care
• Pharmacology

Background:

• Dyspnea is a primary symptom in Chronic Obstructive Pulmonary Disease (COPD).
• While bronchodilators and non-pharmacological therapies are standard, some patients develop refractory dyspnea.
• Advanced COPD necessitates exploring additional treatment options for persistent breathlessness.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose systemic opioids for refractory dyspnea in severe COPD.
• To determine optimal dosing strategies and assess the impact on patient quality of life.
• To provide evidence-based recommendations for managing severe COPD-related breathlessness.

Main Methods:

• Review of randomized controlled trials investigating low-dose opioid use in COPD patients.
• Analysis of treatment protocols, including low starting doses (e.g., 1.0 mg morphine) and dose titration.
• Assessment of outcomes related to dyspnea relief, side effects, hospital admissions, and mortality.

Main Results:

• Low-dose systemic opioids are an effective palliative treatment for refractory dyspnea in severe COPD.
• Treatment demonstrated safety for symptom reduction, with no increase in hospital admissions or deaths.
• Titration to the lowest effective dose is recommended to balance efficacy and side effects.

Conclusions:

• Low-dose oral opioids should be considered for patients with severe COPD experiencing refractory dyspnea impacting daily activities.
• This therapeutic approach offers a safe and effective option to improve quality of life in advanced COPD.
• Physicians are encouraged to offer a trial of low-dose opioids for refractory dyspnea management.